Ligand Pharmaceuticals Incorporated
LGND
Rang in aandelen
#3107
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Aandeelprijs
$291.18
Laatst gesynchroniseerd: 2026-07-31
Marktkapitalisatie
$5.84B
Verandering (1 dag)
-1.73%
Verandering (1 jaar)
60.30%
Land
US
Handel Ligand Pharmaceuticals Incorporated (LGND)
Categorie
Healthcare
Operationele marge voor Ligand Pharmaceuticals Incorporated (LGND)
Operationele marge op October 2026 TTM: 34.74%
Volgens de meest recente financiële rapporten en aandelenkoers van Ligand Pharmaceuticals Incorporated is de huidige operationele marge (TTM) 34.74%. Eind 2023 had het bedrijf een operationele marge van 9.09%.
Geschiedenis van de operationele marge van Ligand Pharmaceuticals Incorporated van 2000 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 34.74% | -356.76% |
| 2024 | -13.53% | -248.84% |
| 2023 | 9.09% | 486.45% |
| 2022 | 1.55% | -95.86% |
| 2021 | 37.47% | 63.41% |
| 2020 | 22.93% | -581.72% |
| 2019 | -4.76% | -107.31% |
| 2018 | 65.11% | 34.94% |
| 2017 | 48.25% | 19.82% |
| 2016 | 40.27% | 5.97% |
| 2015 | 38.00% | 24.96% |
| 2014 | 30.41% | -0.33% |
| 2013 | 30.51% | 1,567.21% |
| 2012 | 1.83% | -178.88% |
| 2011 | -2.32% | -98.14% |
| 2010 | -124.50% | 386.33% |
| 2009 | -25.60% | -92.81% |
| 2008 | -356.13% | -23.69% |
| 2007 | -466.69% | 289.79% |
| 2006 | -119.73% | 698.73% |
| 2005 | -14.99% | -34.43% |
| 2004 | -22.86% | 68.21% |
| 2003 | -13.59% | -45.62% |
| 2002 | -24.99% | -17.55% |
| 2001 | -30.31% | -68.22% |
| 2000 | -95.37% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -98.89% |
US
|
|
| -149.01% | -104.29% |
US
|
|
| 25.57% | -99.26% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.17% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.